书签 分享 收藏 举报 版权申诉 / 38
上传文档赚钱

类型2小时糖耐量试验的临床意义91课件.ppt

  • 上传人(卖家):晟晟文业
  • 文档编号:3863570
  • 上传时间:2022-10-19
  • 格式:PPT
  • 页数:38
  • 大小:1.08MB
  • 【下载声明】
    1. 本站全部试题类文档,若标题没写含答案,则无答案;标题注明含答案的文档,主观题也可能无答案。请谨慎下单,一旦售出,不予退换。
    2. 本站全部PPT文档均不含视频和音频,PPT中出现的音频或视频标识(或文字)仅表示流程,实际无音频或视频文件。请谨慎下单,一旦售出,不予退换。
    3. 本页资料《2小时糖耐量试验的临床意义91课件.ppt》由用户(晟晟文业)主动上传,其收益全归该用户。163文库仅提供信息存储空间,仅对该用户上传内容的表现方式做保护处理,对上传内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!
    4. 请根据预览情况,自愿下载本文。本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
    5. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007及以上版本和PDF阅读器,压缩文件请下载最新的WinRAR软件解压。
    配套讲稿:

    如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。

    特殊限制:

    部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。

    关 键  词:
    小时 糖耐量 试验 临床意义 91 课件
    资源描述:

    1、2小时糖耐量试验的临床意义小时糖耐量试验的临床意义 Finnish Academy Research Fellow芬兰赫尔辛基大学及芬兰赫尔辛基大学及 国立公共卫生研究院国立公共卫生研究院北大糖尿病论坛北大糖尿病论坛2007年年 5 月月12日,日,北京北京乔青乔青 MD,Ph.D 糖尿病诊断试验糖尿病诊断试验:历史回顾历史回顾糖尿病糖尿病症状症状尿糖尿糖空腹血糖空腹血糖糖耐量糖耐量(1913年年)Jacobsen A.Biochem Z 51:443,1913Normal Glucose Homeostasis Daytime Profile(N=12,health;Mean+95%CI)O

    2、wens D,Zinman B&Bolli G:Lancet 358,739,2001Meal Times80400Insulin(mU/L)08.0013.0016.00 19.00 hGlucose(mmol/L)8426Bimodal distribution of glucoseand prevalence of retinopathy and proteinuria in Pima Indians Knowler WC etc.Diabetes Metab Rev 6:1-27,1990Copyright 1994 BMJ Publishing Group Ltd.McCane,D

    3、R et al.BMJ 1994;308:1323-85 year cumulative incidence(top)and prevalence(bottom)of retinopathy in relation to tenths of 2hPG,FPG,and HBa1c 现用诊断标准现用诊断标准 NDDG1979:FPG=7.8 mmol/l and 75g OGTT at,1,1,2 hours WHO 1980:adopted the NDDG criteria,2h glucose=11.1 mmol/l after 75g load as“金标准金标准”WHO 1985:sli

    4、ghtly modified the WHO 1980 criteria ADA 1997:FPG 7.8 mmol/l to 7.0 mmol/l,Not use OGTT WHO 1999:adopted the FPG 7.0 mmol/l,retained the 2h OGTT WHO/IDF 2006:no changes except for some terms 什么是糖耐量异常什么是糖耐量异常?1.均值均值+2标准差标准差2.血糖双峰分布血糖双峰分布,小血管病变小血管病变3.大血管病变大血管病变:心脑血管及外周血管病变心脑血管及外周血管病变 Dysglycemia Normo

    5、glycemia in Acute and Stable CV Disease Consecutive pts:2107 in-pts;2854 out-pt elective CV consults in Europe(71%men;mean age 66)OGTT/old DM in 1587(75%)acute&1857(66%)elective pts before discharge or within 2 mo.NGTIFGIGTKnown DMNew DM29%35%22%22%31%30%15%10%3%3%020406080100%AcuteElectiveThe DECOD

    6、E Study(http:/www.ktl.fi/decode/index.html)Diabetes Epidemiology:Collaborative analysis Of Diagnostic criteria in Europe Classification of individuals-the DECODE StudyDiscrepancy of FPG and 2hPG criteria in the DECODA study Diabetologia 2000;43:1470-1475051015202530Both2hPG=11.1FPG=7.0 30-39 40-49 5

    7、0-59 60-69 70-79 80-89Prevalence(%)of newly diagnosed DM in DECODE populationsThe DECODE group,Diabetes Care 2003;26:61-69.051015202530354045IFG&IGTIGTIFG 30-39 40-49 50-59 60-69 70-79 80-89 Prevalence(%)of IGT but not IFG increases with age in DECODE populationThe DECODE group,Diabetes Care 2003;26

    8、:61-69.Hazards ratio for all-cause mortality in subjects without prior history of diabetes Adj.for age,cohorts,sex,chol,BMI,SBP,smoking 2-hour plasma glucose(mmol/l)7.06.16.96.1 11.17.811.07.8Fasting plasma glucose(mmol/l)2.52.01.51.00.50.0Hazard ratioAdapted from DECODE Study Group,Lancet 1999;354:

    9、6176211.000.580.520.560.590.820.470.500.540.660.840.920.00.20.40.60.81.01.2=11.10Known DM=7.006.10-6.995.75-6.094.75-5.7413.08.54.0Fasting plasma glucose(mmol/l)FrequencyHazard ratioDECODE,Diabetes Care 26:688-696Hazard ratio for mortality by FPG categories,the DECODA StudyFPG(mmol/l)6.1(n=5547)6.1-

    10、6.9(n=462)7.0(n=297)P for trendCVDModel 1Model 2111.4(0.9-2.1)1.1(0.7-1.7)2.0(1.3-3.1)0.9(0.5-1.5)0.0060.83All-causeModel 1Model 2111.2(0.9-1.6)0.9(0.7-1.3)1.8(1.3-2.5)0.9(0.6-1.3)0.0010.81Model 1:Adjusted for age,sex,cohort,BMI,sysBP,Chol and smokingModel 2:Additional adjustment for 2hPG DECODA Stu

    11、dy Group,Diabetologia 2004;47:385-394Hazard ratio for mortality by 2hPG categories,the DECODA Study2hPG(mmol/l)7.8(n=4753)7.8-11.0(n=1106)11.1(n=447)P for trendCVDModel 1Model 2111.3(0.9-1.9)1.3(0.9-1.9)3.2(2.2-4.7)3.4(2.1-5.4)0.0010.001All-causeModel 1Model 2111.3(1.0-1.7)1.4(1.0-1.8)2.9(2.2-3.8)3.

    12、0(2.2-4.2)0.0010.001Model 1:Adjusted for age,sex,cohort,BMI,sysBP,Chol and smokingModel 2:Additional adjustment for FPG DECODA Study Group,Diabetologia 2004;47:385-394Non-diabetic DiabeticFollow-upBaseline 2hPGNGTIGTNon-diabeticCHD incidence 5.39.716.1CVD mortality3.17.98.7All-cause mortality7.612.8

    13、15.5Incidence density(no./per 1000 person-years)Qiao et al.Diabetes Care 2003;26:2910-2914Hazard ratio(95%CI)by glucose status at baseline and at follow-upFollow-upNon-diabeticDiabeticBaseline 2hPGNGTIGTNon-diabeticCHD incidence11.5(1.0-2.3)1.8(1.0-3.2)CVD mortality12.3(1.4-3.9)1.7(0.8-3.5)All-cause

    14、 mortality11.7(1.1-2.4)1.5(0.9-2.5)Adjusted for age,sex,WHR,SBP,Chol,HDL and smokingQiao et al.Diabetes Care 2003;26:2910-2914Effect of intensive glycemic control on the risk for any type of macrovascular eventsC Stettler,Am Heart J 2006;152:27-38STOP-NIDDM Trial(1)Myocardial infarctionAnginaRevascu

    15、larization procedureCardiovascular deathCerebrovascular event or strokePeripheral vascular diseaseAny cardiovascular event FavoursAcarboseFavoursPlaceboChiasson JL JAMA 2003;23:290:486-94The main changes from baseline to 3 years:AcarbosePlaceboSTOP-NIDDM Trial(3)Body Weight(kg)-1.15 0.26BMI(kg/m2)-0

    16、.60 -0.12Waist(cm)-0.62 0.17SysBP(mmHg)-0.97 -0.05DiasBP(mmHg)-2.8 -1.42hPG(mmol/L)-0.63 0.04Triglycerides(mmol/L)-0.18 -0.04All p 50 conventional pts-CV event 11 yrs post DCCT;17 yrs altogetherGHb Results:DCCT EndEDIC EndIntensive7.4(1.1)7.9(1.3)Conventional9.1(1.5)7.8(1.3)Intensive Insulin Rx&CVD:

    17、T1 DM DCCT/EDIC NEJM 2005;353:2643Primary CV CompositeRRR=42%(9-63)RRR after adj.for updated GHb until end of DCCT(or CV event during DCCT):16%(-64 57)P=0.61Intensive Insulin Rx&CVD:T1 DM DCCT/EDIC NEJM 2005;353:2643MI,Stroke,CV DeathRRR=57%(12-79)Chronic G Lowering&CVD:IGT STOP NIDDM Analysis:Chias

    18、son et al.JAMA 2003;290:486HR 0.51(0.28-0.95)(i.e.32/686 vs.15/682 MI,Angina,Revasc,CV Death,CHF,Stroke,or PVD)Copyright 1994 BMJ Publishing Group Ltd.McCane,D R et al.BMJ 1994;308:1323-8ROC curves for prevalence of retinopathy(top)and nephropathy(bottom)for 2hPG(-),FPG(.),and HbA1(-)concentrations1

    19、-SpecificityRelative risk(95%CI)of mortality significantly increased in subjects with IGTHazards ratio for mortality in diabetic patients according to FPG Mortality FPG 7.0 mmol/l FPG 7.0 mmol/l adjusted for 2-hour glucose CVD 1.5(1.21.9)1.2(0.91.7)CHD 1.4(1.02.0)1.1(0.71.7)Stroke 1.9(1.23.2)1.7(0.9

    20、3.1)All-cause 1.7(1.41.2)1.2(1.01.4)The DECODE group,Arch Intern Med 2001;161:397-404Adjusted for age,center,sex,cholesterol,BMI,BP,smoking Hazards ratio for mortality in diabetic patients according to 2-hour glucose Mortality 2-hour glucose 11.1 mmol/l 2-hour glucose 11.1 mmol/l adjusted for FPG CV

    21、D 1.6(1.22.0)1.4(1.01.9)CHD 1.6(1.22.3)1.6(1.02.4)Stroke 1.7(1.03.0)1.3(0.72.5)All-cause 1.9(1.72.2)1.7(1.52.1)The DECODE group,Arch Intern Med 2001;161:397-404Adjusted for age,center,sex,cholesterol,BMI,BP,smoking TiQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMbJ8G4D1A-w*t!

    22、qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfNcK9H5E2B+x(u$rZoWkThQeMbJ7G4D1z-w*t!qYmVjSgOdLaI6F3B0y)v%s#pXlUiQfNcK8H5E2A+x*u$rZnWkThPeMbJ7G4C1z-w&t!qYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$qZnWkShPeMaJ7F4C1z)w&t!pYmUjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)w&s!pYmUjRfOcL9H6E3B+y(u%r#oWlTiQeNb

    23、J8G5D1A-x*t$qYnVkSgPdMaI7F4C0z)v&s!pXmUjRfOcK9H6E2B+y(u%rZoWlThQeNbJ8G4D1A-w*t$qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfNcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZnWkThPeMbJ7G4C1z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkShPeMaJ7G4C1z)w&t!pYmVjRgOcL9I6E3B0y(v

    24、%r#oXlTiQfNbK8G5D2A-x*u$qZnWkShPdMaJ7F4C1z)w&s!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeNbK8G5D1A-x*t$qZnVkSgPdMaI7F4C0z)v&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-w*t$qYnVkSgPdLaI7F3C0z)v&s#pXmUiRfOcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgPdLaI6F3C0y)v&s#pXlUiRfNcK9H5E2A+x(u$rZoWkThPeMbJ7G4D1z-w&t!qYmVjSgO

    25、dL9I6F3B0y)v%s#oXlUiQfNcK8H5E2A+x*u$rZnWkThPeMaJ7G4C1z-w&t!pYmVjRgOdL9I6E3B0y(v%s#oXlTiQfNbK8H5D2A-x*u$qZnWkShPdMaJ7F4C1z)w&t!pYmUjRgOcL9I6E3B+y(v%r#oXlTiQeNbK8G5D2A-x*t$qZnVkShPdMaI7F4C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK9H2A-x*t$qZnVkShPdMaI7F4C0z)w&

    26、s!pXmUjRfOcL9H6E3B+y(u%r#oWlTiQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMbJ8G4D1A-w*t!qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfNcK9H5E2B+x(u$rZoWkThQeMbJ7G4D1z-w*t!qYmVjSgOdLaI6F3B0y)v%s#pXlUiQfNcK8H5E2A+x(u$rZnWkThPeMbJ7G4C1z-w&t!qYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$qZnWkShPe

    27、MaJ7F4C1z)w&t!pYmVjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)w&s!pYmUjRfOcL9H6E3B+y(u%r#oWlTiQeNbJ8G5D1A-x*t$qZnVkSgPdMaI7F4C0z)v&s!pXmUjRfOcK9H6E2B+y(u%rZoWlThQeNbJ8G4D1A-w*t$qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfOcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x

    28、(u$rZnWkThPeMbJ7G4D1z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNG4D1z-w*t!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZoWkThPeMbJ7G4D1z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkShPeMaJ7G4C1z)w&t!pYmVjRgOdL9I6E3B0y(v%s#oXlTiQfNbK8H5D2A-x*u$qZnWkShPdMaJ7F4C1z)w&s!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeNb

    29、K8G5D1A-x*t$qZnVkShPdMaI7F4C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-w*t$qYnVkSgPdLaI7F3C0z)v&s#pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMbJ8G4D1A-w*t!qYnVjSgPdLaI6F3C0y)v&s#pXlUiRfNcK9H5E2A+x(u$rZoWkThPeMbJ7G4D1z-w&t!qYmVjSgOdLaI6F3B0y)v%s#pXlUiQfNcK8H5E2A+x*u$rZnWkThPeMaJ7G4C1z-w&t!pYmVjRgOdL9I6E3B0y(v

    30、%s#oXlTiQfNbK8H5D2A+x*u$qZnWkShPeMaJ7F4C1z)w&t!pYmUjRgOcL9I6E3B*u$rZnWkThPeMaJ7G4C1z-w&t!pYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$qZnWkShPeMaJ7F4C1z)w&t!pYmUjRgOcL9I6E3B+y(v%r#oXlTiQeNbK8G5D2A-x*t$qZnVkShPdMaJ7F4C0z)w&s!pYmUjRfOcL9H6E3B+y(u%r#oWlTiQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK

    31、9H6E2B+y(u%rZoWlThQeNbJ8G4D1A-w*t$qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfNcK9H5E2B+x(u$rZoWkThQeMbJ7G4D1z-w*t!qYmVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZnWkThPeMbJ7G4C1z-w&t!qYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$rZnWkShPeMaJ7G4C1z)w&t!pYmVjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)w&

    32、s!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeJ7G4C1z)w&t!pYmVjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C1z)w&s!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeNbK8G5D1A-x*t$qZnVkSgPdMaI7F4C0z)v&s!pXmUjRfOcK9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-w*t$qYnVkSgPdLaI7F3C0z)v&s#pXmUiRfOcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgOdLa

    33、I6F3C0y)v&s#pXlUiRfNcK9H5E2A+x(u$rZoWkThPeMbJ7G4D1z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkThPeMaJ7G4C1z-w&t!pYmVjRgOdL9I6E3B0y(v%s#oXlTiQfNbK8H5D2A-x*u$qZnWkShPdMaJ7F4C1z)w&s!pYmUjRgOcL9I6E3B+y(v%r#oXlTiQeNbK8G5D2A-x*t$qZnVkShPdMaI7F4C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8Gz)w&t!pY

    34、mUjRgOcL9I6E3B+y(v%r#oXlTiQeNbK8G5D2A-x*t$qZnVkShPdMaI7F4C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlTiQeNbJ8G5D1A-x*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMbJ8G4D1A-w*t!qYnVjSgPdLaI6F3C0y)v&s#pXmUiRfNcK9H5E2B+x(u$rZoWkThQeMbJ7G4D1z-w*t!qYmVjSgOdLaI6F3B0y)v%s#pXlUiQfNcK8H5E2A+x*u$rZnWkThPeMbJ7

    35、G4C1z-w&t!qYmVjRgOdL9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$qZnWkShPeMaJ7F4C1z)w&t!pYmUjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShP9I6F3B0y(v%s#oXlUiQfNbK8H5D2A+x*u$qZnWkShPeMaJ7F4C1z)w&t!pYmVjRgOcL9I6E3B0y(v%r#oXlTiQfNbK8G5D2A-x*u$qZnVkShPdMaJ7F4C0z)w&s!pYmUjRfOcL9H6E3B+y(u%r#oWlTiQeNbK8G5D1A-x*t$qZn

    36、VkSgPdMaI7F4C0z)v&s!pXmUjRfOcK9H6E2B+y(u%rZoWlThQeNbJ8G4D1A-w*t$qYnVjSgPdLaI7F3C0y)v&s#pXmUiRfOcK9H5E2B+x(u%rZoWkThQeMbJ8G4D1z-w*t!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZnWkThPeMbJ7G4D1z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2At!qYnVjSgOdLaI6F3C0y)v%s#pXlUiRfNcK8H5E2A+x(u$rZoWkThPeMbJ7G4D1

    37、z-w&t!qYmVjSgOdL9I6F3B0y)v%s#oXlUiQfNcK8H5D2A+x*u$rZnWkShPeMaJ7G4C1z)w&t!pYmVjRgOdL9I6E3B0y(v%s#oXlTiQfNbK8H5D2A-x*u$qZnWkShPdMaJ7F4C1z)w&s!pYmUjRgOcL9H6E3B+y(v%r#oWlTiQeNbK8G5D2A-x*t$qZnVkShPdMaI7F4C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-w*t$qYnVkSgPdLaI7F3C0z)v&s#pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMbJ8C0z)w&s!pXmUjRfOcL9H6E2B+y(u%r#oWlThQeNbJ8G5D1A-w*t$qYnVkSgPdMaI7F3C0z)v&s!pXmUiRfOcK9H6E2B+x(u%rZoWlThQeMb

    展开阅读全文
    提示  163文库所有资源均是用户自行上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作他用。
    关于本文
    本文标题:2小时糖耐量试验的临床意义91课件.ppt
    链接地址:https://www.163wenku.com/p-3863570.html

    Copyright@ 2017-2037 Www.163WenKu.Com  网站版权所有  |  资源地图   
    IPC备案号:蜀ICP备2021032737号  | 川公网安备 51099002000191号


    侵权投诉QQ:3464097650  资料上传QQ:3464097650
       


    【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。

    163文库